We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




AI-Enabled 'Future' FDG-PET Brain Scans Predict Brain Changes in Alzheimer Patients

By MedImaging International staff writers
Posted on 05 Jul 2023
Print article
Image: An algorithm can forecast brain development from images obtained in FDG-PET examinations (Photo courtesy of Freepik)
Image: An algorithm can forecast brain development from images obtained in FDG-PET examinations (Photo courtesy of Freepik)

Previous research has shown that artificial intelligence (AI) can predict clinical symptomatic changes in neuropsychiatric disorders based on baseline neuroimaging data. However, successful studies predicting actual longitudinal changes in the entire brain are relatively few compared to those focusing on specific longitudinal alterations like hippocampal volume. Now, a preliminary study indicates that a deep learning-based algorithm can accurately predict brain development up to six years following an initial Alzheimer’s disease assessment via FDG-PET scans.

Researchers at the German Center for Neurodegenerative Diseases (DZNE, Göttingen, Germany) employed a convolutional neural network (CNN) to train an algorithm on the first two FDG-PET scans to predict the third scan acquired in elderly (>+ 55 years) participants, who received FDG-PET imaging in three consecutive years. The algorithm successfully predicted the overall future FDG-PET signal for the entire brain—namely, the metabolic reduction, which indicates neuronal activity. The tool was also capable of anticipating a future signal decline, or metabolic reduction, reflecting a loss of neuronal activity.

The algorithm's capabilities could be extended to predict FDG-PET outcomes up to six years following the initial scan, by sequentially using model output as input for subsequent-year predictions. Additionally, the tool seemed to detect ongoing neurodegenerative processes at baseline as it predicted a significant signal decline in year 2 in Alzheimer’s disease (AD) patients, especially in AD-prone regions such as the bilateral inferior temporal and parietal regions, and the posterior cingulate cortex. Possessing a tool that forecasts longitudinal FDG-PET scans based on scans obtained at baseline and one year later could enhance patient care. This study explores new territory, as the prediction of longitudinal metabolic changes in the brain, as measured by FDG-PET, has rarely been examined before.

“Such an algorithm would allow physicians to read an anticipated ‘future’ FDG-PET brain scan as they would in their normal routine, but years in advance,” said Elena Doering, a Ph.D. student at DZNE. “We hope that our work can provide clinical benefit in two ways: improving early diagnosis or providing reliable prognosis; and allowing individual prediction of brain pathological changes over time.”

Related Links:
DZNE 

New
Prostate Cancer MRI Analysis Tool
DynaCAD Urology
Ultrasonic Pocket Doppler
SD1
New
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
New
Cylindrical Water Scanning System
SunSCAN 3D

Print article

Channels

MRI

view channel
Image: An AI tool has shown tremendous promise for predicting relapse of pediatric brain cancer (Photo courtesy of 123RF)

AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans

Many pediatric gliomas are treatable with surgery alone, but relapses can be catastrophic. Predicting which patients are at risk for recurrence remains challenging, leading to frequent follow-ups with... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.